SCHEMBL20812657

SCHEMBL20812657

O=C1CCC(n2cc(-c3ccccc3)nn2)C(=O)N1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 4/20 0.61
▸ CRBN Q96SW2 12/20 0.49
▸ DDB1 Q16531 11/20 0.49
▸ IKZF3 Q9UKT9 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ CHRM2 P08172 1/20 0.49
▸ OPRM1 P35372 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ PSEN1 P49768 1/20 0.45
▸ PSEN2 P49810 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ APH1B Q8WW43 1/20 0.45
▸ NCSTN Q92542 1/20 0.45
▸ APH1A Q96BI3 1/20 0.45
▸ PSENEN Q9NZ42 1/20 0.45
▸ DRD2 P14416 1/20 0.44
▸ DRD4 P21917 1/20 0.44
▸ DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20812154 0.87 SRC (0.48) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL20812163 0.87 SRC (0.48) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL20812342 0.84 SRC (0.48) SRCCRBNDDB1PSEN1PSEN2
SCHEMBL31444080 0.84 CRBN (0.55) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL20812705 0.83 CRBN (0.54) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL22711376 0.83 SRC (0.42) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL20812343 0.83 CRBN (0.51) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL24414160 0.81 PSEN1 (0.42) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL22711511 0.80 CRBN (0.42) SRCCRBNDDB1IKZF3ALDH1A1
SCHEMBL20812175 0.80 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 SRC 4229/4885CRBN 23/4885DDB1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback